Panacea Biotec Publishes Audited Q4 FY26 Financial Results in Newspapers
Panacea Biotec published its audited standalone and consolidated financial results for Q4 FY26 on June 1, 2026. These results were announced following board approval on May 30, 2026. The company also highlighted new product launches.
This is a routine compliance filing regarding the publication of financial results, which has already been announced. It does not introduce new material information that would significantly impact the company's stock.
The announcement is a routine disclosure of financial results publication and does not contain significant positive or negative financial news.
Panacea Biotec Limited has published the audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026. This publication was made in accordance with Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
The results were released in two newspapers: Business Standard (English) and Desh Sewak (Punjabi) on June 01, 2026. The company had previously intimated the approval of these financial results on May 30, 2026, following a review by the Audit Committee on May 29, 2026, and approval by the Board of Directors on May 30, 2026.
The financial statements were prepared following Indian Accounting Standards (Ind-AS) as per Section 133 of the Companies Act, 2013. The detailed financial results, including comparative periods, are available on the stock exchange websites (NSE and BSE) and the company's website. The announcement also highlights new product launches, including NikoMom and Staart Prime, with a quote from Dr. Rajesh Jain, Chairman & Managing Director, emphasizing the company's commitment to child safety and care.
What to do with a filing like this
Panacea Biotec Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Panacea Biotec Limited. Read the original for the full detail.